Your Health, We Care
Release date: 2026-01-28 17:50:52 Recommended: 10
Combination of this class of drugs with Revuforj is not recommended; if co-administration is unavoidable, healthcare providers will need to monitor you more frequently for QTc interval prolongation.
The severe adverse reactions of Revuforj mainly include severe hypersensitivity reactions, differentiation syndrome, and cardiac rhythm abnormalities that may lead to QT interval prolongation.
These reactions can be life-threatening. Discontinue the drug immediately and seek emergency medical care if you experience breathing problems or wheezing, tachycardia, swelling of the face or throat, difficulty swallowing, generalized rash or hives, dizziness or fainting, or general malaise accompanied by nausea, vomiting, stomach cramps and joint pain.
This is a severe and potentially fatal complication caused by the release of immune mediators from cancer cells, typically occurring within 3 to 41 days after the initiation of treatment. Symptoms include fever, cough or shortness of breath, rash, severe headache, confusion, dizziness, rapid weight gain, swelling in multiple parts of the body (e.g., extremities, neck), and decreased urine output. If any related symptoms occur, you must contact your healthcare provider immediately for early intervention to prevent organ damage.
In addition, Revuforj may cause rare but dangerous cardiac rhythm abnormalities, such as QT interval prolongation, which in turn increases the risk of torsades de pointes. The risk is higher in elderly patients, those with a relevant family history, abnormal electrolyte levels, or patients concurrently taking other drugs that affect cardiac rhythm. Inform your healthcare provider at once if you experience fainting or notice irregular, rapid, or skipped heartbeats.
Inform your healthcare provider of all other medications you are taking, including prescription drugs, over-the-counter drugs, vitamins, and herbal supplements. Drug interactions may occur when Revuforj is used with other medications, which can further trigger adverse reactions. Be sure to inform your healthcare provider emphatically if you are taking the following drugs:
Strong CYP3A4 inhibitors: e.g., clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal, and grapefruit. Your healthcare provider will need to adjust and reduce your dosage of Revuforj.
Strong or moderate CYP3A4 inducers: e.g., phenobarbital, phenytoin, rifampicin. Combination of this class of drugs with Revuforj is not recommended.
Drugs that prolong the QT interval: e.g., antipsychotics, antiarrhythmics, antidepressants, and antihistamines.
